About these ads

Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘duke retractions’ Category

Shoddy Photoshopping sinks immunology paper

with 25 comments

Screen Shot 2014-06-30 at 12.30.32 PMBiochemical Journal has pulled a 2006 paper for an undisclosed “background subtraction box” in an image - which, if you take a not-particularly-close look at the figure to the right, means somebody added a black rectangle over the control lane.

Here’s the notice: for “Phosphorylation of Ser158 regulates inflammatory redox-dependent hepatocyte nuclear factor-4a transcriptional activity”: Read the rest of this entry »

About these ads

RIP, Ed Rickards: Duke watchdog who covered Anil Potti case dies at 72

with 3 comments

dukeIt’s unusual for us to post obituaries on Retraction Watch — we’ve published just one so far in three-and-a-half years — but we wanted to pause for a moment to note the passing of a tireless crusader for transparency and accountability whose electronic path crossed with ours a number of times since 2012 because of our shared interest in the case of Anil Potti.

We learned of the death of Ed Rickards this weekend while Ivan was attending ScienceOnline 2014. The Duke Chronicle, the university’s student newspaper, reported on February 5: Read the rest of this entry »

Written by Ivan Oransky

March 2, 2014 at 4:57 pm

Former Duke researcher charged with embezzlement has a paper retracted

with 10 comments

j app physA new retraction notice in the Journal of Applied Physiology gives only a hint at the problems in the paper, but what it does say has led us to a story about one of its co-authors.

Here’s the notice, from a team at Duke: Read the rest of this entry »

Another retraction for Anil Potti, with an inscrutable notice

with 4 comments

We’ve seen a lot of retraction notices for work by Anil Potti — 10, to be precise, along with 7 corrections and one partial retraction notice. As notices go, they tend to be pretty complete. So when we saw one in CHEST for this 2008 abstract, we were expecting something similar.

Instead, we were confused.

Here’s the notice: Read the rest of this entry »

Written by Ivan Oransky

October 5, 2012 at 11:30 am

Lead author of major breast cancer study announced at ASCO co-authored two corrected papers with Anil Potti

with 7 comments

One of the biggest stories so far out of the American Society of Clinical Oncology (ASCO) meeting that just ended in Chicago was that of T-DM1, which, according to Ivan’s Reuters colleagues, “extended the length of time breast cancer patients lived without their disease getting worse.” (The news was even the subject of an embargo break.)

The widely-hailed study of Roche’s drug was led by Duke’s Kimberly Blackwell, who told The New York Times: Read the rest of this entry »

Written by Ivan Oransky

June 4, 2012 at 6:02 pm

A “retraction in part” for Anil Potti and colleagues, in Molecular Cancer Therapeutics

with one comment

A partial retraction has joined the ten retractions and five corrections of Anil Potti’s papers, this one of a 2008 paper in Molecular Cancer Therapeutics. The move comes 14 months after the retraction of the Nature Medicine paper upon which much of the Molecular Cancer Therapeutics paper was based.

Here’s the notice: Read the rest of this entry »

Tenth Potti retraction appears, in Clinical Cancer Research

with 3 comments

Anil Potti and his colleagues have retracted another paper, “Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma,” originally published in the December 15, 2009, issue of Clinical Cancer Research.

According to the notice: Read the rest of this entry »

Follow

Get every new post delivered to your Inbox.

Join 35,810 other followers